#1 Clinical Trials Search in Europe

Erenumab

Erenumab, also known as Aimovig, is a monoclonal antibody that has shown promising results in clinical trials for the prevention of migraine. This article explores the use of erenumab in various clinical studies, examining its effectiveness, safety profile, and potential impact on patients’ quality of life. We’ll delve into the neurophysiological, biomolecular, and psychological aspects of erenumab treatment in chronic migraine patients, as well as its long-term effects and potential use during pregnancy.

Table of Contents

What is Erenumab?

Erenumab, also known by its brand name Aimovig, is a revolutionary medication designed for the prevention of migraines. It belongs to a new class of drugs called calcitonin gene-related peptide (CGRP) inhibitors[1]. Erenumab is a monoclonal antibody, which means it’s a type of protein that can target specific molecules in the body. In this case, it targets the CGRP receptor, which plays a crucial role in migraine development[2].

How Does Erenumab Work?

Erenumab works by blocking the CGRP receptor in the brain. CGRP is a protein that is involved in the transmission of pain signals and inflammation in the nervous system. By blocking this receptor, erenumab can prevent the onset of migraine attacks[3]. This mechanism of action is different from traditional migraine medications, which often work by constricting blood vessels or altering brain chemistry after a migraine has already begun.

Conditions Treated with Erenumab

Erenumab is primarily used for the prevention of migraine headaches. It has been shown to be effective in treating both episodic migraines (occurring less than 15 days per month) and chronic migraines (occurring 15 or more days per month)[1]. Some studies have also investigated its use in other headache disorders, such as:

  • Hemicrania Continua: A rare type of continuous headache that occurs on one side of the head[4].
  • Medication Overuse Headache: A condition where frequent use of pain relief medications actually leads to more headaches[5].

How is Erenumab Administered?

Erenumab is administered as a subcutaneous injection, which means it’s injected just under the skin. It typically comes in pre-filled syringes or autoinjector pens, making it possible for patients to self-administer the medication at home after proper training[5]. The usual dosage is either 70 mg or 140 mg once a month, depending on the patient’s needs and response to treatment[6].

Effectiveness of Erenumab

Clinical trials have shown promising results for erenumab in migraine prevention:

  • Reduction in Migraine Days: Many patients experience a significant decrease in the number of days they have migraines each month[5].
  • Improved Quality of Life: Patients often report better overall functioning and less disability due to migraines[6].
  • Decreased Use of Acute Medications: With fewer migraine attacks, patients typically need less medication for immediate pain relief[5].
It’s important to note that the effectiveness can vary from person to person, and it may take several months to see the full benefits of the treatment.

Side Effects and Safety

Erenumab is generally well-tolerated, but like all medications, it can have side effects. The most common side effects reported in clinical trials include:

  • Injection site reactions (redness, pain, or swelling where the injection is given)
  • Constipation
  • Muscle cramps
  • Fatigue
Serious side effects are rare but can include allergic reactions[5]. It’s important to discuss any side effects with your healthcare provider.

Ongoing Research and Future Directions

Research on erenumab is ongoing, with several studies exploring its long-term effects and potential use in different patient populations. Some areas of current research include:

  • Biomarkers for Treatment Response: Scientists are looking for genetic or other biological markers that might predict which patients will respond best to erenumab[2].
  • Brain Changes: Studies are using advanced imaging techniques to understand how erenumab affects brain structure and function in migraine patients[7].
  • Pregnancy Safety: A registry has been established to monitor the safety of erenumab use during pregnancy[8].
  • Combination with Other Treatments: Researchers are exploring how erenumab might work alongside other migraine treatments for enhanced effectiveness[9].
These ongoing studies aim to further improve our understanding of erenumab and optimize its use in migraine prevention.

Aspect Details
Efficacy – Significant reduction in monthly migraine days – High percentage of patients achieving ≥50% reduction in migraine frequency – Decrease in acute migraine-specific medication use
Safety – Generally well-tolerated – Most common side effects: injection site reactions, constipation – Rare serious adverse events – Long-term safety studies ongoing
Administration – Subcutaneous injection – Monthly doses of 70 mg or 140 mg – Self-administration possible with proper training
Quality of Life Impact – Improved physical functioning – Enhanced emotional well-being – Reduced migraine-related disability – Better overall health status
Neurophysiological Effects – Changes in brain functional connectivity – Alterations in pain processing networks – Reduction in central sensitization
Biomolecular Aspects – Potential changes in miRNA expression (e.g., miR-34a-5p, miR-382-5p) – Influence on inflammatory biomarkers
Special Populations – Studies in chronic and episodic migraine – Ongoing research in pregnancy (GENESIS study) – Effective in patients who failed previous preventive treatments

FAQ

  • What is erenumab and how does it work? Erenumab (Aimovig) is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. It works by blocking CGRP, a protein involved in migraine pain signaling, potentially reducing the frequency and severity of migraine attacks.
  • How is erenumab administered in clinical trials? In most clinical trials, erenumab is administered as a subcutaneous injection, typically once a month. Doses used in trials range from 70 mg to 140 mg, with some studies exploring both dosages to determine optimal effectiveness.
  • What are the primary outcomes measured in erenumab clinical trials? Primary outcomes often include changes in monthly migraine days, percentage of patients achieving at least a 50% reduction in migraine frequency, and assessment of adverse events to evaluate safety and tolerability.
  • Are there any notable side effects of erenumab observed in clinical trials? While erenumab is generally well-tolerated, some reported side effects include injection site reactions, constipation, and muscle spasms. Serious adverse events are rare, but ongoing studies continue to monitor long-term safety.
  • How does erenumab affect patients' quality of life? Clinical trials have shown that erenumab can significantly improve patients' quality of life by reducing migraine frequency and severity. This is measured using various questionnaires assessing physical functioning, emotional well-being, and overall health status.

Ongoing Clinical Trials on Erenumab

  • Study on Reducing Chronic Migraine Days with CGRP Antibodies and Botulinum Toxin A in Adults Aged 18-70

    Recruiting

    3 1 1
    Investigated drugs:
    Norway

  • A Study of Erenumab Compared to Placebo for Children and Teenagers With Chronic Migraine to Test How Well It Works and How Safe It Is

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Hungary Italy Poland

  • Study of Erenumab Compared to Placebo for Children and Adolescents with Episodic Migraine to Reduce Monthly Migraine Days

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Hungary Italy Poland Portugal +1

Glossary

  • Erenumab: A monoclonal antibody medication used for migraine prevention that targets the calcitonin gene-related peptide (CGRP) receptor.
  • Calcitonin Gene-Related Peptide (CGRP): A protein involved in pain signaling and inflammation, particularly in migraine headaches.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to specific substances in the body, used in the treatment of various diseases including migraines.
  • Subcutaneous Injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.
  • Chronic Migraine: A condition characterized by having 15 or more headache days per month, with at least 8 of those days featuring migraine symptoms, for more than 3 months.
  • Episodic Migraine: Migraine headaches occurring less than 15 days per month.
  • Nociceptive Withdrawal Reflex (NWR): A neurophysiological technique used to study spinal nociceptive transmission and pain processing.
  • MicroRNA (miRNA): Small non-coding RNA molecules that play a role in gene regulation and are being studied as potential biomarkers in migraine research.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique used to visualize internal body structures, often used in migraine studies to examine brain structure and function.
  • Quality of Life (QoL): A measure of an individual's overall well-being, including physical, mental, and social aspects, often assessed in clinical trials to determine treatment effectiveness.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Open-Label Extension (OLE) Study: A type of clinical trial where participants and researchers know which treatment is being administered, often following a double-blind study to assess long-term safety and efficacy.

References

  1. https://clinicaltrials.gov/study/NCT02630459
  2. https://clinicaltrials.gov/study/NCT04265755
  3. https://clinicaltrials.gov/study/NCT04674020
  4. https://clinicaltrials.gov/study/NCT04303845
  5. https://clinicaltrials.gov/study/NCT02174861
  6. https://clinicaltrials.gov/study/NCT04825678
  7. https://clinicaltrials.gov/study/NCT03773562
  8. https://clinicaltrials.gov/study/NCT06150781
  9. https://clinicaltrials.gov/study/NCT04361721